Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma,
Ph.D., M.D., president and chief executive officer, will present an
update of the company’s product development programs at 9:30 am EDT on
Thursday, June 11, 2009, at the 8th Annual Needham Life
Sciences Conference in New York City.
The update will include information about Geron’s portfolio of
anti-cancer therapies, including its telomerase inhibitor drug
(imetelstat sodium - GRN163L) and its telomerase therapeutic vaccine
(GRNVAC1). The presentation will also include a review of the company’s
human embryonic stem cell development programs for spinal cord injury
(GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1).
The audio and slide presentation will be available at the following web
site address: http://www.wsw.com/webcast/needham30/gern/.
The presentation will be archived for replay at the same address within
24 hours of the live presentation for a period of 30 days.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment
of cancer and chronic degenerative diseases, including spinal cord
injury, heart failure and diabetes. The company is advancing an
anti-cancer drug and a cancer vaccine that target the enzyme telomerase
through multiple clinical trials. Geron is also the world leader in the
development of human embryonic stem cell (hESC)-based therapeutics. The
company has received FDA clearance to begin the world’s first human
clinical trial of a hESC-based therapy: GRNOPC1 for acute spinal cord
injury. For more information about Geron, visit www.geron.com.
Geron Corporation
Anna Krassowska, Ph.D., 650-473-7765
Investor
and Media Relations
info@geron.com
